J Korean Med Sci.  2015 Jun;30(6):688-693. 10.3346/jkms.2015.30.6.688.

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus

• Hwang JH
• Lee JH
• Hwang JH
• Chung KM
• Lee EJ
• Yoon YJ
• Moon MK
• Kim JS
• Won KS
• Lee CS

• KMID: 2160594
• DOI: http://doi.org/10.3346/jkms.2015.30.6.688

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of ear infections. We attempted to evaluate the clinical usefulness of arbekacin in treating chronic suppurative otitis media (CSOM) by comparing its clinical efficacy and toxicity with those of vancomycin. Efficacy was classified according to bacterial elimination or bacteriologic failure and improved or failed clinical efficacy response. Ninety-five subjects were diagnosed with CSOM caused by MRSA. Twenty of these subjects were treated with arbekacin, and 36 with vancomycin. The bacteriological efficacy (bacterial elimination, arbekacin vs. vancomycin: 85.0% vs. 97.2%) and improved clinical efficacy (arbekacin vs. vancomycin; 90.0% vs. 97.2%) were not different between the two groups. However, the rate of complications was higher in the vancomycin group (33.3%) than in the arbekacin group (5.0%) (P=0.020). In addition, a total of 12 adverse reactions were observed in the vancomycin group; two for hepatotoxicity, one for nephrotoxicity, eight for leukopenia, two for skin rash, and one for drug fever. It is suggested that arbekacin be a good alternative drug to vancomycin in treatment of CSOM caused by MRSA.

Keyword

Arbekacin; Vancomycin; Methicillin-resistant Staphylococcus aureus; Otitis Media

MeSH Terms

Adult
Aged
Anti-Bacterial Agents/administration & dosage
Chronic Disease
Dibekacin/administration & dosage/*analogs & derivatives
Female
Humans
Male
Methicillin-Resistant Staphylococcus aureus/*drug effects
Middle Aged
Otitis Media, Suppurative/diagnosis/*drug therapy/microbiology
Staphylococcal Infections/diagnosis/*drug therapy/microbiology
Treatment Outcome
Vancomycin/*administration & dosage
Young Adult
Anti-Bacterial Agents
Dibekacin
Vancomycin

Reference

1. Lee SH, Park CW, Tae K, Park IB, Hue YD, Kang JO, Kim JW. Comparative analysis of therapeutic effect between topical vancomycin and systemic vancomycin in otorrhea by methicillin-resistent Staphylococcus aureus (MRSA) infection. Korean J Otolaryngol-Head Neck Surg. 1999; 42:704–708.

2. Lee ES, Song JS, Hwang SJ, Suh HK, Cheong HJ. Possibility of reciprocal infection of methicillin-resistant Staphylococcus aureus between medical personnel and patients undergoing middle ear surgery. ORL J Otorhinolaryngol Relat Spec. 2001; 63:87–91.

3. Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol. 2002; 122:827–830.

4. MacNeil SD, Westerberg BD, Romney MG. Toward the development of evidence-based guidelines for the management of methicillin-resistant Staphylococcus aureus otitis. J Otolaryngol Head Neck Surg. 2009; 38:483–494.

5. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006; 44:3883–3886.

6. Ida T, Okamoto R, Shimauchi C, Okubo T, Kuga A, Inoue M. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol. 2001; 39:3115–3121.

7. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1997; 39:471–476.

8. Gilbert DN, Leggett JE. Aminoglycosides: anti-infective therapy. In : Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone/Elsevier;2010.

9. Federspil P, Schatzle W, Tiesler E. Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. J Infect Dis. 1976; 134:S200–S205.

10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med. 2007; 4:e296.

11. Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu J, Chang MS, Yum YK. Clinical efficacy and safety with arbekacin for methicillin-resistant Staphylococcus aureus (MRSA) infections. Korean J Med. 2003; 65:239–244.

12. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001; 10:785–792.

13. Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med. 1987; 106:728–733.

14. Lee SK, Yeo SG, Hong SM, Sim JS, Hong CK, Lee YC, Kim SW, Cha CI. Bacteriology of chronic otitis media: changing of detection rate of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Korean J Otorhinolaryngol-Head Neck Surg. 2008; 51:9–15.

15. Sim JH, Kim KT, Lee SH, Yun SH. Bacteriologic study of chronic suppurative otitis media. Korean J Otolaryngol-Head Neck Surg. 1997; 40:819–826.

16. Yu YI, Cha CI, Lee IY, Byun JY, Cho JS. Current bacteriology of chronic suppurative otitis media. Korean J Otolaryngol-Head Neck Surg. 2004; 47:607–611.

17. Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents. 2008; 31:99–106.

18. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340:493–501.

19. Kim JM, Park ES, Jeong JS, Kim KM, Kim JM, Oh HS, Yoon SW, Chang HS, Chang KH, Lee SI, et al. Multicenter surveillance study for nosocomial infections in major hospitals in Korea. Nosocomial Infection Surveillance Committee of the Korean Society for Nosocomial Infection Control. Am J Infect Control. 2000; 28:454–458.

20. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49:507–514.

21. Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012; 51:1–13.

22. Hamilton-Miller JM, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1995; 35:865–868.

23. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW. Efficacy of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in in vitro infective endocarditis model. Infect Chemother. 2003; 35:145–153.

24. Lee JY, Oh WS, Ko KS, Heo ST, Moon CS, Ki HK, Kiem S, Peck KR, Song JH. Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus. J Korean Med Sci. 2006; 21:188–192.

25. Lee J, Kim CK, Roh KH, Lee H, Yum JH, Yong D, Lee K, Chong Y. In vitro activity of arbekacin against clinical isolates of Staphylococcus species and gram-negative bacilli. Korean J Lab Med. 2007; 27:292–297.

26. Lee SM, Song EJ, Yang EK, Bae IK, Jeong SH, Kim JM, Lee EY, Chang CL. Antimicrobial activities of arbekacin against recent isolates of Staphylococcus aureus in Korean hospitals. Korean J Clin Microbiol. 2006; 9:13–17.

27. Wie SH, Kang JH, Huh DH, Lee DG, Kim SI, Kim YR, Choi JH, Kim JH, Yoo JH, Hur JK, et al. Antimicrobial activities of arbekacin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus species. Korean J Infect Dis. 2001; 33:254–260.

28. Chong Y, Lee K, Shin J, Shin H, Lim J. Activities of arbekacin against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J Korean Soc Chemother. 1997; 15:319–327.

29. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis. 2012; 31:1663–1666.

30. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study. Infect Chemother. 2013; 45:62–68.